PAUL G. LINAWEAVER
To the editor: In the article by Data and Nies "Drugs Five Years Later: Dextran 40" (Ann Intern Med 81:500-504, 1974), the authors overlooked one important clinical use of low-molecular-weight dextran. In the treatment of decompression sickness (dysbarism), including both actual human cases and in controlled animal experiments, low-molecular-weight dextran has proved to be an important adjunct to recompression (pressure) therapy in decreasing morbidity and mortality. The mode of action is still a matter of considerable interest and controversy. Postulated modes of action include  prevention of hemoconcentration by plasma-expanding properties (1);  lipemic clearing effect (2);  inhibition of
LINAWEAVER PG. Dextran in Recompression Therapy. Ann Intern Med. ;82:287. doi: 10.7326/0003-4819-82-2-287_1
Download citation file:
Published: Ann Intern Med. 1975;82(2):287.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use